Inclusion Criteria:  Histopathological diagnosis: lymphoma; Age 14 to 65, no gender limitation; ECOG physical condition score was 0~3; Life expectancy &gt;6 months; did not receive recombinant human erythropoietin treatment within 30 days before the first day; Complete liver and kidney function (creatinine ≦1.5*ULN, BUN≦1.5*ULN, ALT≦2*ULN, AST≦2*ULN, total bilirubin ≦1.5*ULN;ULN: upper limit of normal value); Willing to sign the informed consent, can understand and abide by the requirements of the study.  Exclusion Criteria:  Active infections requiring intravenous antibiotic treatment and any active malignancies (except lymphomas); Grade III or IV heart failure, uncontrolled hypertension or hypotension, and associated risk or event of thromboembolism; Severe hepatic and renal insufficiency; Patients who have received radiotherapy or chemotherapy for other tumors (except lymphoma) within 6 months; other anemia diseases (such as aplastic anemia, thalassemia, myelodysplastic syndrome, etc.); Inability to understand and follow the study protocol or inability to sign the informed consent.